4974 — Takara Bio Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapNeutral

Annual income statement for Takara Bio, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	JAS	JAS	JAS	JAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	46,086	67,699	78,142	43,505	45,039
Cost of Revenue
Gross Profit	31,872	49,211	44,765	26,908	26,067
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	32,643	39,556	56,962	40,709	43,235
Operating Profit	13,443	28,143	21,180	2,796	1,804
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	13,552	27,532	21,224	2,853	1,998
Provision for Income Taxes
Net Income After Taxes	9,581	19,908	16,048	1,510	1,088
Minority Interest
Net Income Before Extraordinary Items
Net Income	9,547	19,850	16,013	1,481	1,043
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	9,547	19,849	16,012	1,480	1,042
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	86.9	175	135	20	17.1
Dividends per Share